Drug Delays Recurrence in People With Early-Stage Breast Cancer
People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor.
Thanks to Lifesaving Cancer Research18,000,000cancer survivors in the United States are living with, through, and beyond their disease.
Your donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now